191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

OT1-02-06: DETECT III – A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2−Negative Metastatic Breast Cancer and HER2−Positive Circulating Tumor Cells.

10.1158/0008-5472.sabcs11-ot1-02-06 ◽

2011 ◽

Cited By ~ 1

Author(s):

CA Melcher ◽

W Janni ◽

U Ortmann ◽

B Jäger ◽

B Rack ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Abstract OT1-1-11: DETECT III - A multicenter, randomized, phase III trial to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells

10.1158/0008-5472.sabcs13-ot1-1-11 ◽

2013 ◽

Author(s):

N de Gregorio ◽

F Schochter ◽

C Melcher ◽

C Hagenbeck ◽

TWP Friedl ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial

Abstract OT1-1-10: DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumorcells

10.1158/0008-5472.sabcs12-ot1-1-10 ◽

2012 ◽

Cited By ~ 3

Author(s):

CA Melcher ◽

JW Janni ◽

A Schneeweiss ◽

PA Fasching ◽

CD Hagenbeck ◽

...

Keyword(s):

Breast Cancer ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial

10.1158/1538-7445.sabcs20-pd3-12 ◽

2021 ◽

Author(s):

Tanja Fehm ◽

Volkmar Mueller ◽

Maggie Banys-Paluchowski ◽

Peter A Fasching ◽

Thomas WP Friedl ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2045-1 ◽

2012 ◽

Vol 134 (1) ◽

pp. 283-289 ◽

Cited By ~ 70

Author(s):

Marta Pestrin ◽

Silvia Bessi ◽

Fabio Puglisi ◽

Alessandro M. Minisini ◽

Giovanna Masci ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Single Agent ◽

Metastatic Breast ◽

Proof Of Concept ◽

Her2 Positive ◽

Multicenter Phase

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study

The Oncologist ◽

10.1634/theoncologist.2012-0448 ◽

2013 ◽

Vol 18 (3) ◽

pp. 257-264 ◽

Cited By ~ 86

Author(s):

Sandra M. Swain ◽

Michael S. Ewer ◽

Javier Cortés ◽

Dino Amadori ◽

David Miles ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-pd05-07 ◽

2011 ◽

Author(s):

EM Olson ◽

LM Flores ◽

JS Najita ◽

C Curley ◽

J Jeong ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Her2 Positive

Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07)

European Journal of Cancer Care ◽

10.1111/ecc.13253 ◽

2020 ◽

Vol 29 (4) ◽

Author(s):

Eva M. Ciruelos ◽

Alvaro Montaño ◽

César A. Rodríguez ◽

Encarnación González‐Flores ◽

Ana Lluch ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 512-512 ◽

Cited By ~ 76

Author(s):

A. D. Seidman ◽

D. Berry ◽

C. Cirrincione ◽

L. Harris ◽

L. Dressler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

BMC Cancer ◽

10.1186/1471-2407-13-202 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 41

Author(s):

Yi Liu ◽

Qian Liu ◽

Tao Wang ◽

Li Bian ◽

Shaohua Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Predictive Biomarker ◽

Breast Cancer Patients ◽

Her2 Positive